SHIVA GUPTA to Glioblastoma
This is a "connection" page, showing publications SHIVA GUPTA has written about Glioblastoma.
Connection Strength
1.622
-
Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. J Natl Cancer Inst. 2016 May; 108(5).
Score: 0.243
-
Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts. Clin Cancer Res. 2014 Jul 15; 20(14):3730-41.
Score: 0.219
-
Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models. Clin Cancer Res. 2024 Aug 01; 30(15):3287-3297.
Score: 0.111
-
ATM inhibition exploits checkpoint defects and ATM-dependent double strand break repair in TP53-mutant glioblastoma. Nat Commun. 2024 Jun 21; 15(1):5294.
Score: 0.110
-
Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization. Sci Transl Med. 2024 Feb 14; 16(734):eadj5962.
Score: 0.108
-
Central Nervous System Distribution of the Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD1390: Implications for the Treatment of Brain Tumors. J Pharmacol Exp Ther. 2022 10; 383(1):91-102.
Score: 0.097
-
Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma. Neuro Oncol. 2021 12 01; 23(12):2042-2053.
Score: 0.092
-
Brain Distribution of Berzosertib: An Ataxia Telangiectasia and Rad3-Related Protein Inhibitor for the Treatment of Glioblastoma. J Pharmacol Exp Ther. 2021 12; 379(3):343-357.
Score: 0.091
-
In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling. Mol Cancer Ther. 2021 06; 20(6):1009-1018.
Score: 0.088
-
Molecular profiling of long-term IDH-wildtype glioblastoma survivors. Neuro Oncol. 2019 11 04; 21(11):1458-1469.
Score: 0.080
-
Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma. Nat Commun. 2018 11 21; 9(1):4904.
Score: 0.075
-
Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma. Mol Cancer Ther. 2017 Dec; 16(12):2735-2746.
Score: 0.069
-
Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma. J Pharmacol Exp Ther. 2017 11; 363(2):136-147.
Score: 0.069
-
DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme. Cancer Res. 2017 01 01; 77(1):198-206.
Score: 0.065
-
The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma. Clin Cancer Res. 2015 Apr 15; 21(8):1916-24.
Score: 0.057
-
Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts. Clin Cancer Res. 2012 Aug 01; 18(15):4070-9.
Score: 0.048